LLY

1,007.5

-0.79%↓

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

LLY

1,007.5

-0.79%↓

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

LLY

1,007.5

-0.79%↓

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

LLY

1,007.5

-0.79%↓

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

LLY

1,007.5

-0.79%↓

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

Inicio・Lista de Acciones・Johnson and Johnson

Johnson and Johnson

Abierto

SectorSanidad

230.78 0.16

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

229.1

Máximo

231.74

Métricas clave
By Trading Economics
Ingresos	119M 5.2B
Ventas	-502M 24B
P/B Media del Sector	25.629 51.415
BPA	2.7
Rentabilidad por dividendo	2.35
Margen de beneficios	21.756
Empleados	138,200
EBITDA	182M 6.4B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+14.9% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	2.35% 2.34%
Próximas Ganancias	15 jul 2026
Fecha Próximo Dividendo	9 jun 2026
Próxima Fecha de Ex Dividendo	26 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-40B 533B
Apertura anterior	230.62
Cierre anterior	230.78

Noticias sobre sentimiento de mercado

By Acuity

33%

67%

94 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

154.93 / 155.895 Soporte y Resistencia

Johnson and Johnson Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2026, 13:27 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

23 abr 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

22 abr 2026, 11:27 UTC

Ganancias

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

14 abr 2026, 19:38 UTC

Ganancias

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 abr 2026, 14:13 UTC

Ganancias

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 abr 2026, 12:57 UTC

Ganancias

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 abr 2026, 11:19 UTC

Ganancias

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 abr 2026, 10:34 UTC

Ganancias

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

14 abr 2026, 10:20 UTC

Charlas de Mercado

Ganancias

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

14 abr 2026, 10:20 UTC

Charlas de Mercado

Ganancias

J&J's Tremfya Sales Continue to Surge -- Market Talk

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

14 abr 2026, 10:20 UTC

Ganancias

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Comparación entre iguales

Cambio de precio

Johnson and Johnson previsión

Precio Objetivo

By TipRanks

14.9% repunte

Estimación a 12 Meses

Media 264.75 USD 14.9%

Máximo 285 USD

Mínimo 240 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Johnson and Johnson Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

Comprar

Mantener

Vender

De acuerdo con 18 analistas que ofrecen calificaciones bursátiles a para Johnson and Johnson Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

154.93 / 155.895Soporte y Resistencia

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

94 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.